CD8A and melanoma: The immunotherapy based on SyBVs with T-EVs significantly enhanced the infiltration of CD8+ T cells and NK cells at the tumor site, facilitated IFN-γ production, strengthened tumor-specific CTL responses, increased the levels of tumor-specific IgG associated with Th1 immune responses, and effectively inhibited the growth and metastasis of melanoma.